Axitinib bests second-line sorafenib for kidney cancer: Commentary
Publication
, Journal Article
George, DJ
Published in: Oncology Report
July 1, 2011
Duke Scholars
Published In
Oncology Report
ISSN
1548-5323
Publication Date
July 1, 2011
Issue
JULY-AUGUST
Start / End Page
19
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2011). Axitinib bests second-line sorafenib for kidney cancer: Commentary. Oncology Report, (JULY-AUGUST), 19.
George, D. J. “Axitinib bests second-line sorafenib for kidney cancer: Commentary.” Oncology Report, no. JULY-AUGUST (July 1, 2011): 19.
George DJ. Axitinib bests second-line sorafenib for kidney cancer: Commentary. Oncology Report. 2011 Jul 1;(JULY-AUGUST):19.
George, D. J. “Axitinib bests second-line sorafenib for kidney cancer: Commentary.” Oncology Report, no. JULY-AUGUST, July 2011, p. 19.
George DJ. Axitinib bests second-line sorafenib for kidney cancer: Commentary. Oncology Report. 2011 Jul 1;(JULY-AUGUST):19.
Published In
Oncology Report
ISSN
1548-5323
Publication Date
July 1, 2011
Issue
JULY-AUGUST
Start / End Page
19
Related Subject Headings
- Oncology & Carcinogenesis